Evolution of Urticaria Pigmentosa into Indolent Systemic Mastocytosis: Abnormal Immunophenotype of Mast Cells without Evidence of c-kit Mutation ASP-816-VAL

@article{Noack2003EvolutionOU,
  title={Evolution of Urticaria Pigmentosa into Indolent Systemic Mastocytosis: Abnormal Immunophenotype of Mast Cells without Evidence of c-kit Mutation ASP-816-VAL},
  author={F. Noack and L. Escribano and K. Sotlar and R. N{\'u}{\~n}ez and K. Schuetze and P. Valent and H. Horny},
  journal={Leukemia \& Lymphoma},
  year={2003},
  volume={44},
  pages={313 - 319}
}
Mastocytosis comprises a heterogeneous group of hematological disorders which are morphologically defined by proliferation and accumulation of tissue mast cells in one or more organs. Clinical manifestations of mastocytosis range from disseminated maculopapular skin lesions (=urticaria pigmentosa [UP]) that may spontaneously regress to highly aggressive neoplasms like mast cell leukemia or mast cell sarcoma. Recently, it could be shown that systemic mastocytosis (SM) is a clonal disorder often… Expand
Cutaneous Mastocytosis in Childhood—Update from the Literature
Diagnostic value of tryptase in anaphylaxis and mastocytosis.
  • L. Schwartz
  • Medicine
  • Immunology and allergy clinics of North America
  • 2006
The genetic basis of mast cell activation disease - looking through a glass darkly.
  • G. Molderings
  • Medicine, Biology
  • Critical reviews in oncology/hematology
  • 2015
Prognostic value of KIT mutation in gastrointestinal stromal tumors.
Mast cell tryptase in sera of patients with Crohn's disease and mastocytosis
...
1
2
...

References

SHOWING 1-10 OF 28 REFERENCES
Recent Advances in Mastocytosis Research
Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.
Biology, classification and treatment of human mastocytosis.
  • P. Valent
  • Medicine
  • Wiener klinische Wochenschrift
  • 1996
Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Mastocytosis: molecular mechanisms and clinical disease heterogeneity.
...
1
2
3
...